Harentz
2021-01-05T00:00:05+00:00
Pfizer和Moderna只测重症者，轻症和无症状都不在计算在内
China's Sinovac vaccine has "general efficacy" of 50.4% in Brazil trials, says Butantan
January 12, 2021, 11:31 AM
RIO DE JANEIRO, Jan 12 (Reuters) - A coronavirus vaccine developed by China's Sinovac showed "general efficacy" of 50.38% in a late-stage trial in Brazil, the company's local partners said on Tuesday, revealing a more modest figure after pressure for more transparency.
科兴的巴西伙伴公布科兴的疫苗有效率是50.38%
On Thursday, Butantan officials had celebrated results showing 78% efficacy against mild COVID-19 cases, a rate they have since described as "clinical efficacy."
上星期四巴西官员公布了科兴疫苗对轻症有效率是78%
Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo, said the new figure included infections that were so mild or asymptomatic that they did not need clinical care. (Reporting by Gabriel Stargardter and Pedro Fonseca Editing by Brad Haynes)
聖保羅Butantan biomedical的医疗主任说新的有效率是包括轻症和无症状者。
China's Sinovac vaccine has "general efficacy" of 50.4% in Brazil trials, says Butantan
January 12, 2021, 11:31 AM
RIO DE JANEIRO, Jan 12 (Reuters) - A coronavirus vaccine developed by China's Sinovac showed "general efficacy" of 50.38% in a late-stage trial in Brazil, the company's local partners said on Tuesday, revealing a more modest figure after pressure for more transparency.
科兴的巴西伙伴公布科兴的疫苗有效率是50.38%
On Thursday, Butantan officials had celebrated results showing 78% efficacy against mild COVID-19 cases, a rate they have since described as "clinical efficacy."
上星期四巴西官员公布了科兴疫苗对轻症有效率是78%
Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo, said the new figure included infections that were so mild or asymptomatic that they did not need clinical care. (Reporting by Gabriel Stargardter and Pedro Fonseca Editing by Brad Haynes)
聖保羅Butantan biomedical的医疗主任说新的有效率是包括轻症和无症状者。